Abstract:Defining the components of an HIV immunogen that could induce effective CD8+ T cell responses is critical to vaccine development. We addressed this question by investigating the viral targets of CD8+ T cells that potently inhibit HIV replication in vitro, as this is highly predictive of virus control in vivo. We observed broad and potent ex vivo CD8+ T cell-mediated viral inhibitory activity against a panel of HIV isolates among viremic controllers (VC, viral loads <5000 copies/ml), in contrast to unselected HIV-infected HIV Vaccine trials Network (HVTN) participants. Viral inhibition of clade-matched HIV isolates was strongly correlated with the frequency of CD8+ T cells targeting vulnerable regions within Gag, Pol, Nef and Vif that had been identified in an independent study of nearly 1000 chronically infected individuals. These vulnerable and so-called "beneficial" regions were of low entropy overall, yet several were not predicted by stringent conservation algorithms. Consistent with this, stronger inhibition of clade-matched than mismatched viruses was observed in the majority of subjects, indicating better targeting of clade-specific than conserved epitopes. The magnitude of CD8+ T cell responses to beneficial regions, together with viral entropy and HLA class I genotype, explained up to 59% of the variation in viral inhibitory activity, with magnitude of the T cell response making the strongest unique contribution. However, beneficial regions were infrequently targeted by CD8+ T cells elicited by vaccines encoding full-length HIV proteins, when the latter were administered to healthy volunteers and HIV-positive ART-treated subjects, suggesting that immunodominance hierarchies undermine effective anti-HIV CD8+ T cell responses. Taken together, our data support HIV immunogen design that is based on systematic selection of empirically defined vulnerable regions within the viral proteome, with exclusion of immunodominant decoy epitopes that are irrelevant for HIV control.

Immune responses induced in HHD mice by multiepitope HIV vaccine based on cryptic epitope modification

Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection

An Immunogen Containing Four Tandem 10E8 Epitope Repeats with Exposed Key Residues Induces Antibodies That Neutralize HIV-1 and Activates an ADCC Reporter Gene.

Epitope-vaccine strategy against HIV-1: today and tomorrow.

The Immunologic Dominance of an Epitope Within a Rationally Designed Poly-Epitope Vaccine is Influenced by Multiple Factors.

Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.

Epitope-Vaccines: A New Strategy to Induce High Levels of Neutralizing Antibodies Against Hiv-1

A New Type Multiple-Epitope DNA Vaccine Against HIV

Phosphoproteomic landscaping of HIV-1 in vitro identified phosphorylated epitopes capable of eliciting CD8+ cytotoxic T cell (CTL) responses in patient samples ex vivo

The Recombinant Immunogen with High‐Density Epitopes of ELDKWA and ELDEWA Induced Antibodies Recognizing Both Epitopes on HIV‐1 Gp41

Identification of Subdominant Cytotoxic T Lymphocyte Epitopes Encoded by Autologous Hiv Type 1 Sequences, Using Dendritic Cell Stimulation and Computer-Driven Algorithm

A Recombinant Multi-Epitope Protein MEP1 Elicits Efficient Long-Term Immune Responses Against HIV-1 Infection

Induction of Multi-Epitopespecific Antibodies Against HIV-1 by Multi-Epitopevaccines

Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches

In Silicodesign of a DNA-based HIV-1 Multi-Epitope Vaccine for Chinese Populations

Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1/Kb transgenic mice

Neutralizing Epitopes in the Membrane-Proximal Region of Hiv-1 Gp41: Genetic Variability and Co-Variation

Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX—a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine

Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope Eldkwa and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines Against Hiv-1

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

Hbcag18-27 Epitope Fused To Hiv-Tat(49-57) Adjuvanted With Cpg Odn Induces Immunotherapeutic Effects In Transgenic Mice